BRCA1-Associated Protein 1 and Enhancer of Zeste Homolog 2: Pathway Interaction and Therapeutic Intervention in Breast Cancer, Mesothelioma, and Lymphoma The introduction of T-cell–based therapeutics ...

CAR T cells are patient-derived, genetically engineered immune cells. They are "living drugs" and constitute a milestone in ...

A phase 2 study to confirm safety and efficacy of MB-105, an autologous CD5-directed CAR T-cell therapy, in relapsed/refractory T-cell lymphoma (R/R TCL). This is an ASCO Meeting Abstract from the ...

To address the challenge, Sino Biological has developed anti-whitlow 218 linker rabbit monoclonal antibodies, which specifically binds to the whitlow 218 linker sequence (GSTSGSGKPGSGEGSTKG). The ...

Cemacabtagene ansegedleucel, an allogeneic chimeric antigen receptor (CAR) T-cell therapy, is being investigated in relapsed/refractory large B-cell lymphoma. The investigational allogeneic chimeric ...

A research team led by Prof. HAN Shuo from the Center for Excellence in Molecular Cell Science of the Chinese Academy of Sciences developed a novel cell-surface protein engineering strategy called ...

Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers testing ...

CD40 is a transmembrane protein belonging to the tumor necrosis factor receptor superfamily. It is predominantly expressed on antigen-presenting cells like B cells, macrophages, and dendritic cells.

A new AI tool that models how variations in peptides change T cell receptor binding could help design immunotherapies with fewer off-target effects. Protein complexes that adorn the surface of T cells ...

Eftilagimod alfa and Keytruda with radiotherapy improved tumor hyalinization/fibrosis rates in resectable soft tissue sarcoma, surpassing the trial's primary endpoint. The combination therapy achieved ...